Drug design for ever, from hype to hope

Página do item simplificado
dc.contributor.authorSeddon, Gavin
dc.contributor.authorLounnas, Valère
dc.contributor.authorMcGuire, Ross
dc.contributor.authorvan den Bergh, Tom
dc.contributor.authorBywater, Robert Paul
dc.contributor.authorOliveira, Laerte [UNIFESP]
dc.contributor.authorVriend, Gerrit
dc.contributor.institutionRadboud Univ Nijmegen
dc.contributor.institutionAdelard Inst
dc.contributor.institutionBioAxis Res
dc.contributor.institutionBioprodict
dc.contributor.institutionUniv Oxford Magdalen Coll
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T14:17:35Z
dc.date.available2016-01-24T14:17:35Z
dc.date.issued2012-01-01
dc.description.abstractIn its first 25 years JCAMD has been disseminating a large number of techniques aimed at finding better medicines faster. These include genetic algorithms, COMFA, QSAR, structure based techniques, homology modelling, high throughput screening, combichem, and dozens more that were a hype in their time and that now are just a useful addition to the drug-designers toolbox. Despite massive efforts throughout academic and industrial drug design research departments, the number of FDA-approved new molecular entities per year stagnates, and the pharmaceutical industry is reorganising accordingly. the recent spate of industrial consolidations and the concomitant move towards outsourcing of research activities requires better integration of all activities along the chain from bench to bedside. the next 25 years will undoubtedly show a series of translational science activities that are aimed at a better communication between all parties involved, from quantum chemistry to bedside and from academia to industry. This will above all include understanding the underlying biological problem and optimal use of all available data.en
dc.description.affiliationRadboud Univ Nijmegen, CMBI, Med Ctr, NL-6525 GA Nijmegen, Netherlands
dc.description.affiliationAdelard Inst, Manchester, Lancs, England
dc.description.affiliationBioAxis Res, NL-5351 SL Berghem, Netherlands
dc.description.affiliationBioprodict, NL-6703 HB Wageningen, Netherlands
dc.description.affiliationUniv Oxford Magdalen Coll, Oxford, England
dc.description.affiliationSão Paulo Fed Univ UNIFESP, São Paulo, Brazil
dc.description.affiliationUnifespSão Paulo Fed Univ UNIFESP, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipNBIC
dc.description.sponsorshipTIPharma
dc.description.sponsorshipBio-Prodict
dc.format.extent137-150
dc.identifierhttp://dx.doi.org/10.1007/s10822-011-9519-9
dc.identifier.citationJournal of Computer-aided Molecular Design. Dordrecht: Springer, v. 26, n. 1, p. 137-150, 2012.
dc.identifier.doi10.1007/s10822-011-9519-9
dc.identifier.fileWOS000299929400030.pdf
dc.identifier.issn0920-654X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/34336
dc.identifier.wosWOS:000299929400030
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofJournal of Computer-aided Molecular Design
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.subjectDrug designen
dc.subjectProtein modelingen
dc.subjectQSARen
dc.subjectG-protein coupled receptorsen
dc.subjectTranslational researchen
dc.subjectReviewen
dc.titleDrug design for ever, from hype to hopeen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000299929400030.pdf
Tamanho:
601.91 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
Em verificação - Geral